B+
Bull case
25%
Probability
Target price
$23.00
+96.7% vs current
CRVS
CorvusDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$16.00
+36.9% vs current
B-
Bear case
30%
Probability
Target price
$9.00
-23.0% vs current
AI sentiment snapshot
Latest data as of 2026-04-15
Recent news sentiment (30D)
-
Unavailable
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+83.3
Score
AI commentary
CRVS remains a cautious monitoring name rather than a clean high-conviction long. Primary-source evidence is real and constructive: management highlighted positive cohort-4 AD data, Phase 2 AD initiation, continuing Phase 3 PTCL enrollment, and cash runway into Q2 2028 after the January financing [#PR-2026-03-12] [#10-K-2026-03-12]. But the deterministic score still leans neutral/slightly negative, and the March 13 ATM expansion adds a tangible dilution overhang [#8-K-2026-03-13]. Net: promising clinical momentum, but still early and financing-sensitive.
RankAlpha Sentiment Codex - 2026-04-15
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-05-13eventSID 2026 atopic dermatitis updateHigh impact
Management said it expects to report additional Phase 1 atopic dermatitis data at the Society of Investigative Dermatology meeting, and the meeting is scheduled for May 13-16, 2026. A cleaner efficacy/safety update could support the recent rerating, but this is still early-stage clinical evidence [#PR-2026-03-12].
2026-06-30catalystFinancing flexibility versus dilution overhangHigh impact
The 10-K said no shares had been sold under the prior $100 million ATM as of December 31, 2025, while the March 13, 2026 8-K expanded the Jefferies facility to up to $200 million and again noted no prior usage under the original agreement. That lowers near-term funding stress after the January financing, but it also creates a visible dilution overhang if the stock stays strong [#10-K-2026-03-12] [#8-K-2026-03-13].
2026-11-30catalystPhase 2 atopic dermatitis execution and broader 2026 immune-disease expansionHigh impact
Corvus said it initiated a randomized Phase 2 atopic dermatitis trial in Q1 2026, expects about 200 patients, anticipates initial China atopic dermatitis cohort results late in 2026, and is advancing planned Phase 2 starts in asthma and hidradenitis suppurativa later this year. Hitting enrollment and showing consistent follow-through would strengthen the pipeline-in-a-product case, but timing and readout risk remain material [#PR-2026-03-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-04-15 • Updated nightlySource: Internal modelMethodology